Article

Study: rubella vaccine may prevent eye disease

Chicago-The rubella vaccine, originally a method for preventing birth defects that can occur when "German measles" are passed from a pregnant woman to her fetus, may now prevent eye disease.

Chicago-The rubella vaccine, originally a method for preventing birth defects that can occur when "German measles" are passed from a pregnant woman to her fetus, may now prevent eye disease.

Researchers at the University of Illinois, Chicago, believe this may explain the disappearance of a chronic inflammatory eye disease that can cause cataracts, glaucoma, and blindness, according to the study published in the September issue of the American Journal of Ophthalmology.

Researchers looked at cases of Fuch's heterochromic iridocyclitis (FHI) in U.S. and foreign-born babies before and after the vaccination was introduced in the United States. Babies who were born abroad, receiving the vaccine later, showed more occurrences of FHI than American babies who received it earlier.

Although the cause of FHI is unknown, antibodies to the rubella virus have been found in the eyes of FHI patients which according to researchers, suggests a link.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.